Arch Therapeutics To Showcase AC5® Advanced Wound System at 2024 SAWC Fall Meeting

Arch Therapeutics, Inc., a developer as well as a marketer in self-assembling products for wound care and biosurgery, has stated its commercial product — AC5 Advanced Wound System, which will be prominently showcased at the upcoming 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall). This conference is scheduled for October 2-5, 2024, at Caesars Palace in Las Vegas. 

SAWC will be attended by different groups, such as Physicians, nurses, and industry professionals. During the conference, Arch's team will display the AC5 Advanced Wound System at booth #334 in the main exhibit hall and at numerous locations. Arch is also looking forward to meeting other companies engaged in wound care and life sciences who may be interested in its patented solution to wound care and unique approach to promoting healing.

Mark your calendars for October 4, 2024, when the poster viewing session will highlight clinical cases demonstrating the usage of AC5 for patients with complex wound management:

1. Successful Management of Tunneling Wounds using Synthetic Self-assembling Peptide Matrix — Will Be Presented by Dr. Misael C. Alonso, MD, FACP, CWSP, FAPWCA. 

2. A Pilot Study of Lower Extremity Wounds Utilizing a Novel Nanoparticle Self-Assembling Peptide — Will Be Presented by Eric J. Lullove, DPM, CWSP, DABLES, FAPWH(c), FFPM, RCPS (Glasg).

Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “AC5 is a new and easy-to-use option for many doctors who treat patients in the operating room or their office. With its self-assembly mechanism of action, AC5 provides a differentiated approach to the management of both acute surgical and chronic wounds. The potential importance of AC5 is underscored by the sheer number of people with non-healing wounds, thought to exceed 6 million in the US alone.”

Norchi continued, "The clinical information presented at SAWC includes a pilot study that assesses healing time and potential cost savings when AC5 is used on complicated post-operative non-healing wounds as well as a case study that assesses the management of a tunnelling wound with AC5. These scenarios add to the growing clinical experience with AC5 in wounds, challenging for patients and many currently available wound modalities.” 

AC5 is FDA-approved for managing partial and full-thickness wounds, including pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. This synthetic self-assembling wound care solution offers clinicians versatile support and functionality throughout all stages of wound healing.